Shenzhen Yahuilong Biotechnology Co., Ltd. (hereinafter referred to as "Yahuilong") was established in 2008 and is a listed company on the Science and Technology Innovation Board (stock code: 688575). The company is headquartered in Baolong Science and Technology City, Baolong Street, Longgang District, Shenzhen. Yahuilong is mainly engaged in the research, development, production, sales and services of in vitro diagnostics (IVD) products in the biopharmaceutical industry. It is a national high-tech enterprise with a large number of independent intellectual property rights and is also a national intellectual property demonstration enterprise. In the first half of 2022, the group's output value was 3.15 billion yuan and tax payments of 105 million yuan.

Yahuilong focuses on R&D and innovation in the field of in vitro diagnosis. It currently has more than 1,500 employees, and the proportion of R&D personnel exceeds 25%. It currently has chemiluminescence, fluorescence immunochromatography, enzyme-linked immunization, immunoblotting, indirect immunofluorescence, colloidal gold The six major in vitro diagnostic technology platforms for immunochromatography, and their products cover business areas such as autoimmunity, infection immunity, liver disease detection, reproductive health, and respiratory testing. More than 300 products are widely used in medical institutions such as hospitals, health centers, community outpatient clinics and third-party testing centers at all levels, and the domestic tertiary hospitals account for more than 56%. While based in the domestic market, Yahuilong is actively developing international markets. Its products have been exported to more than 100 countries and regions in Europe, the Middle East, Southeast Asia, Africa, Australia and the Americas, and have been favored and recognized by global customers.

Yahuilong insists on independent innovation, is guided by market demand and customer service as the purpose, and has established an industrial chain layout from raw material research and development to reagent research and development to production. Over the past decade, Yahuilong has undertaken major scientific and technological projects such as the National Development and Reform Commission, the Ministry of Science and Technology, the Shenzhen Development and Reform Commission, the Shenzhen Industry and Information Technology Bureau, and the Shenzhen Science and Technology Innovation Commission. Among them, "High-throughput fully automatic immunoassay device" and The project of R&D and Industrialization of Supporting Reagents has been approved by the National Development and Reform Commission, and has been approved as a major project in Shenzhen and a key introduction project in Longgang District for four consecutive years. As of June 30, 2022, the company has obtained 133 domestic authorized patents and 17 international patents, accounting for 70% of the patents applied for, and accounting for 50% of the authorized patents.

The company attaches great importance to the cultivation of talent echelons, and has successively worked with the team of Academician Zhuang Hui of Peking University, Academician Yan Xiyun of the Institute of Biophysics of the Chinese Academy of Sciences, Academician Tang Benzhong of the Chinese University of Hong Kong (Shenzhen), Dean Lu Hongzhou of Shenzhen Third People's Hospital, and Southern University of Science and Technology Academician Gu Dongfeng's team, the National Optoelectronics Laboratory of Huazhong University of Science and Technology, the National High-Performance Medical Device Innovation Center and other scientific research institutes and medical institutions cooperate to establish joint laboratories and carry out technical product research. In addition, Yahuilong has also established a training platform for medical testing innovative talents with well-known universities such as Huazhong University of Science and Technology, Guangdong Medical University, and Hunan University of Technology, jointly train master's and doctoral students, and jointly cultivate high-level professional talents.

The company adheres to the mission of "focusing on life and health, striving to make technology benefit mankind", always pursues excellence, constantly provides excellent products and services for the cause of human health, and strives to become a leading enterprise in the field of immunity and an advanced enterprise in global in vitro diagnosis.